Rituximab not superior to azathioprine for EGPA remission maintenance

Sarah Onuora
Nature Reviews Rheumatology · Springer Nature · 2026-11-10 · DOI: 10.1038/s41584-026-01465-4

Аннотация

Nature Reviews Rheumatology, Published online: 10 November 2026; doi:10.1038/s41584-026-01465-4 In the MAINRITSEG clinical trial, treatment with rituximab did not confer an advantage over azathioprine for the maintenance of remission in patients with eosinophilic granulomatosis with polyangiitis.

Читать у издателя →

Похожие статьи